Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 5Unknown 4Recruiting 4Not yet recruiting 4Terminated 2Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 18Thoracic 10Genitourinary 7Head & Neck 6Dermatologic 5Other solid neoplasm 4Sarcoma 2Lymphoid 2Gynecologic 2NET 1Endocrine 1Breast 1

Conditions

Hodgkin Disease 1B-cell Malignancies 1

Interventions

Rituximab 129Cyclophosphamide 122Doxorubicin 62Vincristine 61venetoclax 58Prednisone 57ibrutinib 52Specimen Handling 50fludarabine 47Lenalidomide 47Biopsy 46obinutuzumab 43acalabrutinib 42Etoposide 41fludarabine phosphate 36Magnetic Resonance Spectroscopy 36Cytarabine 35CT-P10 35Dexamethasone 34Methotrexate 29Bendamustine Hydrochloride 27pembrolizumab 26Nivolumab 22blinatumomab 21zanubrutinib 20prednylidene 19Calcium Dobesilate 19deltacortene 18Radiotherapy 18Melphalan 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × tislelizumab × Lymphoid × Clear all
NCT05502250 2026-03-06

HOVON164HL

Stichting Hemato-Oncologie voor Volwassenen Nederland

Phase 2 Active not recruiting
75 enrolled
Lymphoid

Hodgkin Disease

NCT04170283 2025-10-21

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

BeOne Medicines

Phase 3 Active not recruiting
955 enrolled
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡